SEARCH:   Advanced

Blood, 5 February 2009, Vol. 113, No. 6, pp. 1375-1382. Prepublished online as a Blood First Edition Paper on November 6, 2008November 14, 2008; DOI 10.1182/blood-2008-07-168625. This Article Full Text (PDF) Supplemental Figure All Versions of this Article: blood-2008-07-168625v1 blood-2008-07-168625v2 113/6/1375    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Cornelissen, J. J. Articles by Dekker, A. W. Search for Related Content PubMed PubMed Citation Articles by Cornelissen, J. J. Articles by Dekker, A. W. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted July 17, 2008 Accepted October 24, 2008 Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: a prospective sibling donor versus no-donor comparison Jan J. Cornelissen*, Bronno van der Holt, Gregor E.G. Verhoef, Mars B. van 't Veer, Marinus H.J. van Oers, Harry C. Schouten, Gert Ossenkoppele, Pieter Sonneveld, Johan Maertens, Marinus van Marwijk Kooy, Martijn R. Schaafsma, Pierre W. Wijermans, Douwe H. Biesma, Shulamit Wittebol, Paul J. Voogt, Joke W. Baars, Pierre Zachee, Leo F Verdonck, Bob Lowenberg, and Adriaan W. Dekker Erasmus University Medical Center, Rotterdam, Netherlands University Hospital Gasthuisberg, Leuven, Belgium Amsterdam Medical Center, Amsterdam, Netherlands University Hospital Maastricht, Maastricht, Netherlands VU University Medical Center, Amsterdam, Netherlands Isala Clinics-Sophia, Zwolle, Netherlands Medisch Spectrum Twente, Enschede, Netherlands Haga Hospital, Den Haag, Netherlands Sint Antonius Hospital, Nieuwegein, Netherlands Meander MC, Amersfoort, Netherlands Atrium Medical Center, Heerlen, Netherlands Netherlands Cancer Institute, Amsterdam, Netherlands ZNA Stuivenberg, Antwerpen, Belgium University Medical Center, Utrecht, Netherlands * Corresponding author; email: j.cornelissen{at}erasmusmc.nl. While commonly accepted in poor-risk ALL, the role of alloSCT is still disputed in adult patients with standard-risk ALL. We evaluated outcome of patients with ALL in CR1, according a sibling donor versus no-donor comparison. 433 eligible patients were entered in 2 consecutive, prospective studies of whom 288 (67%) were younger than 55 years, in CR1, and eligible to receive consolidation by either an autologous SCT or an alloSCT. AlloSCT was performed in 91 out of 96 patients with a compatible sibling donor. Cumulative incidences of relapse at 5 years were, respectively, 24% and 55% for patients with versus those without a donor (HR: 0.37 (0.23-0.60), P<0.001). Non-relapse mortality estimated 16% (+/- 4) at 5 years following alloSCT. As a result, DFS at 5 years was significantly better in the donor group: 60% versus 42% in the no-donor group (HR: 0.60 (0.41-0.89), P= 0.01). Following risk-group analysis, improved outcome was more pronounced in standard-risk patients with a donor, who experienced an overall survival of 69% at 5 years (p=0.05). In conclusion, standard-risk ALL patients with a sibling donor may show favourable survival following SCT, due to both a strong reduction of relapse and a modest non-relapse mortality. This trial is registered with www.trialregister.nl under trial ID NTR228. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

	Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020